Share This Page
Drugs in ATC Class H02CA
✉ Email this page to a colleague
Drugs in ATC Class: H02CA - Anticorticosteroids
| Tradename | Generic Name |
|---|---|
| MODRASTANE | trilostane |
| ISTURISA | osilodrostat phosphate |
| EXTINA | ketoconazole |
| KETOCONAZOLE | ketoconazole |
| KETOZOLE | ketoconazole |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class H02CA (Anticorticosteroids): exclusivity timing, Orange Book coverage, and generic risk
ATC H02CA “anticorticosteroids” is a narrow therapeutic grouping dominated commercially by steroid receptor antagonists, with most durable IP concentrated in specific active ingredients and their fixed combinations rather than the class broadly. Patent leverage typically sits in (1) core molecule claims, (2) formulation and solid-state/manufacturing improvements, and (3) method-of-use claims tied to specific dosing regimens or indications. Generic entry risk is therefore driven by whether an FDA-listed listed product has a defensible Orange Book patent wall and whether Paragraph IV challenges exist for those listed patents.
Because ATC H02CA is an Anatomical Therapeutic Chemical (ATC) class grouping (not an FDA exclusivity construct) and because “anticorticosteroids” spans multiple potential actives and markets, a complete, asset-level patent and Orange Book map requires product-to-active and NDA-to-RLD anchoring. With no active ingredient list, FDA product identifiers, Orange Book entries, or jurisdictional scope provided, there is not enough information to produce a complete and accurate, patent-number-level landscape.
If sufficient information were available (for example, the specific ATC H02CA active ingredients and the relevant U.S. FDA application numbers / RLDs), the deliverable would include: (i) a timeline of primary and secondary patent expirations by jurisdiction, (ii) Orange Book status and exclusivity windows by NDA/BLA, (iii) Paragraph IV litigation and settlement triggers, (iv) formulation patent coverage by dosage form (tablets, oral suspensions, etc.), and (v) generic entry scenarios tied to FDA readiness.
Which drugs define ATC H02CA “anticorticosteroids,” and how does their patent estate drive market dynamics?
Featured snippet: ATC H02CA “anticorticosteroids” market behavior is driven by molecule-specific exclusivity, plus formulation and dosing-regimen IP. Generic leverage depends on Orange Book patent listings for the specific marketed RLD, not the ATC class label.
H3: What anticorticosteroids are typically in ATC H02CA and what matters for IP strength
For any anticorticosteroid in this class, the IP stack usually follows a repeatable pattern:
- Primary composition-of-matter patents for the active ingredient (often filed in the mid- to late-2000s for most mature brands, depending on the specific drug)
- Secondary patents for:
- tablet composition (excipients, disintegrants, solubility modifiers)
- polymorphs/solid-state forms
- manufacturing process (granulation, compression, coating)
- method-of-use (indication-specific regimens, dose titration, safety monitoring)
- Regulatory exclusivity overlays:
- 5-year new chemical entity (NCE) exclusivity where applicable
- 3-year new clinical investigation exclusivity for label expansions
- orphan exclusivity if an orphan designation exists for the relevant indication
- pediatric exclusivity extensions (6 months) where waived/awarded and tied to eligible exclusivity
H3: Why market dynamics diverge across anticorticosteroid actives
Even within the same ATC bucket, market dynamics diverge by:
- degree of off-label prescribing versus approved label
- patient population size and payer coverage behavior
- necessity of therapeutic drug monitoring
- availability of competitors (including compounded access in certain regions)
- manufacturing complexity and supply concentration
What patents protect anticorticosteroids under ATC H02CA in the U.S. Orange Book, and how many are typically listed?
Featured snippet: Under U.S. Orange Book practice, anticorticosteroid brands often list multiple patent families per RLD, typically one for composition and several for formulation and method-of-use, but the exact count is product-specific.
H3: How Orange Book patent listings translate into generic launch barriers
Orange Book-listed patents generally fall into these buckets:
- Drug substance: composition-of-matter (and sometimes method-of manufacture tied to substance synthesis)
- Drug product: formulation, polymorph/solid-state, and manufacturing
- Use: indication and/or dosing regimen
Generic companies must certify to each Orange Book patent:
- Paragraph I: patent not in force
- Paragraph II: waiting for patent expiry
- Paragraph III: patent expired
- Paragraph IV: non-infringement, invalidity, or unenforceability
A high-count Orange Book estate increases the probability that at least one patent is enforceable at the intended launch time.
H3: How to interpret “number of patents” versus enforcement probability
Asset-level strength matters more than the headcount of patents:
- Multiple overlapping patents across continuation filings can extend exclusivity-like leverage even after a “primary” expiration.
- Weakly supported secondary patents sometimes settle early but still delay launch if they remain listed and litigated.
- Method-of-use patents can block launch even where composition is close to generic-ready, depending on labeling carve-outs and FDA labeling negotiations.
When does anticorticosteroid exclusivity expire, and what are the real timing drivers for generic entry?
Featured snippet: Generic entry timing usually hinges on the last Orange Book patent expiration tied to the RLD and any blocking exclusivity (including pediatric extensions), not on ATC-class level timelines.
H3: Typical exclusivity and patent timeline structure for anticorticosteroids
A U.S. timeline typically includes:
- NDA approval date
- earliest potential 5-year exclusivity end (if NCE eligible)
- 7-year/10-year exclusivity only if a qualifying biologic or orphan scenario exists (not typical for small-molecule anticorticosteroids)
- last patent expiry date among drug substance, drug product, and method-of-use patents listed for the RLD
- potential pediatric extension date if awarded
H3: Why secondary patents shift launch by 6 to 36 months
Even when the active ingredient patent is near expiry, formulation and use patents can:
- block “at-risk” launch by sustaining Paragraph IV litigation
- force a design-around (different polymorph, different excipient system, different dosing language)
- create “carve-out” labeling strategies that still require court outcomes
What Paragraph IV challenges and patent litigation affect anticorticosteroid generics?
Featured snippet: Paragraph IV challenges are product-specific and typically attach to the Orange Book patents listed on the RLD. Without the specific RLD and application number, a litigation map cannot be accurately constructed.
H3: What to look for in litigation outcomes
In anticorticosteroid cases, the most commercially relevant outcomes usually include:
- early dismissal or non-infringement findings for one patent family
- settlement terms tied to delayed launch dates or “at-risk” labeling terms
- injunction scope (whether it blocks full launch or only specific label language)
- stipulations that define the design-around boundaries
H3: How settlements typically define “date-to-market”
Settlement agreements usually convert uncertainty into:
- an agreed delayed approval date
- permitted launch with a specified label (carve-out)
- royalty or license payments in some agreements
- agreed dismissal of remaining asserted patents
A litigation map needs:
- the docketed patents (numbers)
- assignees and challenger firms
- settlement or court order dates
What formulations of anticorticosteroids are protected by patent, and which dosage forms face the highest generic risk?
Featured snippet: For anticorticosteroids, formulation patents often focus on solid-state, excipient systems, and manufacturing process details. Dosage forms with complex release profiles or sensitive bioavailability requirements face higher substitution barriers.
H3: Common formulation-IP focal points
Generic feasibility depends on whether brand protection covers:
- polymorph identity or conversion stability
- dissolution rate and bioequivalence-critical excipients
- manufacturing process parameters affecting impurity profiles
- coatings and release-rate engineering (if applicable)
H3: Why “bioequivalence” is not the same as “freedom to operate”
Even if a generic can meet bioequivalence metrics, it still must avoid:
- infringement of formulation patents (composition, polymorph, process)
- method-of-use patent infringement via label design
How does ATC H02CA compare with adjacent steroid pathway classes for patent durability and competitive entry risk?
Featured snippet: Steroid pathway drugs (including glucocorticoid synthesis and receptor classes) tend to have similar IP stack patterns, but anticorticosteroids can show stronger formulation and use-specific barriers when dosing and monitoring are integral to approved regimens.
H3: Practical differentiators that affect launch pressure
- whether the label requires specific patient selection criteria
- whether the brand includes REMS or restricted distribution programs
- whether generic labeling can be carved out to avoid method-of-use claims
- whether the market includes competing alternative-of-care products
What is the Orange Book status of anticorticosteroid products, and which companies are likely challenging them?
Featured snippet: Orange Book status is tied to the listed RLD and application-specific patent code. Without product identifiers, a reliable company challenge list cannot be produced.
H3: Typical challenger profile in small-molecule anticorticosteroids
Where challenges exist, they are often launched by:
- large generic platforms
- specialty generics focused on specialty dosing and controlled distribution
- “at-risk” filers that have strong formulation capabilities
A reliable listing requires the Orange Book patent set and the challengers tied to each Paragraph IV certification.
Key takeaways
- ATC H02CA “anticorticosteroids” is a class label that does not itself determine exclusivity; generic entry timing is driven by RLD-specific Orange Book patent listings and any blocking exclusivity.
- Patent leverage is most commonly concentrated in formulation/solid-state and method-of-use secondary IP, not solely in the core molecule.
- A credible market and patent landscape for H02CA requires anchoring to specific anticorticosteroid active ingredients and U.S. FDA application/RLD identifiers; without those, patent counts, expiration dates, Orange Book status, and litigation outcomes cannot be stated accurately.
FAQs
- Which ATC H02CA active ingredients are currently marketed in the U.S., and what are their respective RLDs?
- How many Orange Book patents are typically listed for anticorticosteroid RLDs, and how are they split across substance, product, and use?
- What are the most common patent types that delay generic launches for anticorticosteroid tablets?
- How do method-of-use patents and label carve-outs affect Paragraph IV settlement outcomes in anticorticosteroids?
- Which jurisdictions outside the U.S. (EU, UK, JP) most often extend protection for anticorticosteroid formulations?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (accessed via FDA Orange Book).
More… ↓
